|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| LEPEDEEsDADYDYQ SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 451408 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Upstream Regulation | |
|---|---|
| Kinases, in vitro: | |
| References | |
|---|---|
|
Rikova K (2012) CST Curation Set: 14270; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 1mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info |
|
|
Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info |
|
|
Gould WR, Silveira JR, Tracy PB (2004) Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem 279, 2383-93
14594814 Curated Info |
|
|
Kalafatis M (1998) Identification and partial characterization of factor Va heavy chain kinase from human platelets. J Biol Chem 273, 8459-66
9525959 Curated Info |
